563 related articles for article (PubMed ID: 35195008)
21. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
22. Immunological Evaluation of Co-Assembling a Lipidated Peptide Antigen and Lipophilic Adjuvants: Self-Adjuvanting Anti-Breast-Cancer Vaccine Candidates.
Aiga T; Manabe Y; Ito K; Chang TC; Kabayama K; Ohshima S; Kametani Y; Miura A; Furukawa H; Inaba H; Matsuura K; Fukase K
Angew Chem Int Ed Engl; 2020 Sep; 59(40):17705-17711. PubMed ID: 32583549
[TBL] [Abstract][Full Text] [Related]
23. Structural basis of antigenic specificity and design of new vaccines.
Arnon R; Van Regenmortel MH
FASEB J; 1992 Nov; 6(14):3265-74. PubMed ID: 1385242
[TBL] [Abstract][Full Text] [Related]
24. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
[TBL] [Abstract][Full Text] [Related]
25. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
[TBL] [Abstract][Full Text] [Related]
26. Increasing cellular immunogenicity to peptide-based vaccine candidates using a fluorocarbon antigen delivery system.
Francis JN; Thaburet JF; Bonnet D; Sizer PJ; Brown CB; Georges B
Vaccine; 2015 Feb; 33(8):1071-6. PubMed ID: 25573036
[TBL] [Abstract][Full Text] [Related]
27. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
28. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
[TBL] [Abstract][Full Text] [Related]
29. Broadening CD4
Filskov J; Mikkelsen M; Hansen PR; Christensen JP; Thomsen AR; Andersen P; Bukh J; Agger EM
J Virol; 2017 Jul; 91(14):. PubMed ID: 28446674
[TBL] [Abstract][Full Text] [Related]
30. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
Pollack KE; Meneveau MO; Melssen MM; Lynch KT; Koeppel AF; Young SJ; Turner S; Kumar P; Sol-Church K; Mauldin IS; Slingluff CL
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32350119
[TBL] [Abstract][Full Text] [Related]
31. Improving vaccine performance with adjuvants.
Vogel FR
Clin Infect Dis; 2000 Jun; 30 Suppl 3():S266-70. PubMed ID: 10875797
[TBL] [Abstract][Full Text] [Related]
32. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
33. Chemical and Synthetic Biology Approaches for Cancer Vaccine Development.
Hossain F; Kandalai S; Zhou X; Zhang N; Zheng Q
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296526
[TBL] [Abstract][Full Text] [Related]
34. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
Benavides LC; Sears AK; Gates JD; Clifton GT; Clive KS; Carmichael MG; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
Expert Rev Vaccines; 2011 Feb; 10(2):201-10. PubMed ID: 21332269
[TBL] [Abstract][Full Text] [Related]
35. Peptide-based vaccines for cancer immunotherapy.
Brinkman JA; Fausch SC; Weber JS; Kast WM
Expert Opin Biol Ther; 2004 Feb; 4(2):181-98. PubMed ID: 14998777
[TBL] [Abstract][Full Text] [Related]
36. Bursal peptide BP-IV as a novel immunoadjuvant enhances the protective efficacy of an epitope peptide vaccine containing T and B cell epitopes of the H9N2 avian influenza virus.
Liu Y; Shen T; Zhou J; Chen L; Shi S; Wang X; Zhang M; Wang C; Liao C
Microb Pathog; 2021 Sep; 158():105095. PubMed ID: 34280501
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
38. Lipid-protamine-DNA-mediated antigen delivery.
Vangasseri DP; Han SJ; Huang L
Curr Drug Deliv; 2005 Oct; 2(4):401-6. PubMed ID: 16305443
[TBL] [Abstract][Full Text] [Related]
39. The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation.
Chen J; Pompano RR; Santiago FW; Maillat L; Sciammas R; Sun T; Han H; Topham DJ; Chong AS; Collier JH
Biomaterials; 2013 Nov; 34(34):8776-85. PubMed ID: 23953841
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
